Natalizumab: immune effects and implications for therapy

Ann Neurol. 2006 May;59(5):731-2. doi: 10.1002/ana.20877.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Integrin alpha4 / physiology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Natalizumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Natalizumab
  • Integrin alpha4